Pascal Mariona, Chauhan Jitesh, Knol Edward, Bianchini Rodolfo, Castells Mariana, De Las Vecillas Leticia, Hartmann Karin, Izquierdo Elena, Jappe Uta, Jimenez-Rodriguez Teodorikez-Wilfox, Levi-Schaffer Francesca, Mayorga Cristobalina, Poli Aurélie, Redegeld Frank, Santos Alexandra F, Jensen-Jarolim Erika, Bergmann Christoph, Karagiannis Sophia N, Bax Heather J
Immunology Department, CDB, Hospital Clínic de Barcelona; Institut D'investigació Biomèdica August pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Department of Medicine, Universitat de Barcelona, Barcelona, Spain.
Allergy. 2025 Aug;80(8):2097-2112. doi: 10.1111/all.16607. Epub 2025 Jun 12.
The basophil activation test (BAT) is gaining increasing relevance as an ex vivo functional assay in allergy to evaluate IgE-mediated hypersensitivity reactions to food allergens, venoms, and drugs and to monitor tolerance induction. Establishing universal standard operating protocols has been difficult, due to several challenges including variable activation markers, positive control selection, the need for processing fresh blood samples, and the existence of non-releasing individuals. In oncology, BAT is also an emerging promising diagnostic and management tool to assess hypersensitivity reactions to biologics and chemotherapy agents, monitor drug tolerance in desensitisation, and predict and address the safety of novel anti-cancer IgE-based therapeutics. This position paper highlights the emerging significance of BAT in AllergoOncology, in facilitating therapy monitoring, biomarker discovery, and risk stratification. Capitalising on long-acquired expertise in the development of BAT for allergy, we propose research directions and routes to clinical applications of this highly promising tool in AllergoOncology. We advocate the need for enhanced focus on addressing standardisation challenges and leveraging outputs for precision medicine. By linking allergy and oncology, the key remaining limitations can be addressed, with the aim of realising the significant promise of BAT as a robust tool to enhance personalised care in allergy and AllergoOncology.
嗜碱性粒细胞活化试验（BAT）作为一种体外功能检测方法，在过敏领域用于评估对食物过敏原、毒液和药物的IgE介导的超敏反应以及监测耐受性诱导，其相关性日益增加。由于存在多种挑战，包括活化标志物的变异性、阳性对照的选择、处理新鲜血液样本的需求以及非释放个体的存在，建立通用的标准操作方案一直很困难。在肿瘤学中，BAT也是一种新兴的有前景的诊断和管理工具，用于评估对生物制剂和化疗药物的超敏反应、监测脱敏过程中的药物耐受性以及预测和解决新型基于IgE的抗癌疗法的安全性。本立场文件强调了BAT在过敏肿瘤学中的新意义，有助于治疗监测、生物标志物发现和风险分层。利用在开发用于过敏的BAT方面长期积累的专业知识，我们提出了这一极具前景的工具在过敏肿瘤学中的研究方向和临床应用途径。我们主张需要更加关注解决标准化挑战，并利用其成果实现精准医学。通过将过敏和肿瘤学联系起来，可以解决剩下的关键局限性，目的是实现BAT作为一种强大工具的重大前景，以加强过敏和过敏肿瘤学中的个性化护理。
